DK1497296T3 - [1,4]Diazocino[7,8,1-hi]indolderivater som antipsykotiske midler og midler mod obesitet - Google Patents

[1,4]Diazocino[7,8,1-hi]indolderivater som antipsykotiske midler og midler mod obesitet

Info

Publication number
DK1497296T3
DK1497296T3 DK03741766T DK03741766T DK1497296T3 DK 1497296 T3 DK1497296 T3 DK 1497296T3 DK 03741766 T DK03741766 T DK 03741766T DK 03741766 T DK03741766 T DK 03741766T DK 1497296 T3 DK1497296 T3 DK 1497296T3
Authority
DK
Denmark
Prior art keywords
agents
diazocino
indole derivatives
antipsychotic
obesity
Prior art date
Application number
DK03741766T
Other languages
English (en)
Inventor
Hong Gao
Gary Paul Stack
Annmarie Louise Sabb
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1497296T3 publication Critical patent/DK1497296T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
DK03741766T 2002-04-25 2003-04-23 [1,4]Diazocino[7,8,1-hi]indolderivater som antipsykotiske midler og midler mod obesitet DK1497296T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37534902P 2002-04-25 2002-04-25

Publications (1)

Publication Number Publication Date
DK1497296T3 true DK1497296T3 (da) 2006-06-06

Family

ID=29270634

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03741766T DK1497296T3 (da) 2002-04-25 2003-04-23 [1,4]Diazocino[7,8,1-hi]indolderivater som antipsykotiske midler og midler mod obesitet

Country Status (15)

Country Link
US (1) US7012089B2 (da)
EP (1) EP1497296B1 (da)
JP (1) JP4537076B2 (da)
CN (2) CN101003538A (da)
AR (1) AR039668A1 (da)
AT (1) ATE321050T1 (da)
AU (1) AU2003263119B2 (da)
BR (1) BR0309499A (da)
CA (1) CA2481324A1 (da)
DE (1) DE60304188T8 (da)
DK (1) DK1497296T3 (da)
ES (1) ES2260631T3 (da)
MX (1) MXPA04010373A (da)
TW (1) TW200307540A (da)
WO (1) WO2003091257A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
US8685924B2 (en) 2004-08-25 2014-04-01 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
AR052227A1 (es) * 2004-11-05 2007-03-07 Wyeth Corp Metabolitos derivados de [1,4] diazepin [ 6,7,1-ij] quinolina, metodos de preparacion y usos de los mismos
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR051946A1 (es) * 2004-11-05 2007-02-21 Wyeth Corp Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20090203750A1 (en) * 2005-08-24 2009-08-13 Alan Kozikowski 5-HT2C Receptor Agonists as Anorectic Agents
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
TW200806300A (en) * 2006-03-24 2008-02-01 Wyeth Corp New therapeutic combinations for the treatment of depression
AR060088A1 (es) * 2006-03-24 2008-05-21 Wyeth Corp Metodos para tratar trastornos cognitivos y otros afines
CA2644639A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment or prevention of psychotic disorders
WO2007112000A2 (en) * 2006-03-24 2007-10-04 Wyeth Treatment of pain
EP2742936A1 (en) 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
AU2011212930B2 (en) 2010-02-04 2016-02-11 The Board Of Trustees Of The University Of Illinois Highly selective 5-HT(2C) receptor agonists having antagonist activity at the 5-HT(2B) receptor
WO2012030953A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
WO2013133325A1 (ja) * 2012-03-06 2013-09-12 武田薬品工業株式会社 三環性化合物
EP2887804B1 (en) 2012-05-22 2021-01-27 Trustees of Dartmouth College Cycloalkanyl[b]indoles useful as glp-1 modulators
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2016123164A1 (en) 2015-01-29 2016-08-04 The Board Of Trustees Of The University Of Illinois Cyclopropylmethanamines as selective 5-ht(2c) receptor agonists
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE
WO2024118348A1 (en) * 2022-11-29 2024-06-06 Mirati Therapeutics, Inc. Processes and intermediates for synthesis of mrtx0902

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3158619A (en) 1962-06-14 1964-11-24 Searle & Co Certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3235564A (en) 1964-03-27 1966-02-15 Searle & Co Intermediates to certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3335134A (en) 1964-04-02 1967-08-08 Sandoz Ag Certain 3, 4-dihydrofluoreno[1, 9a, 9-e, f]1, 4-diazepin-3(2h)-ones
US3296252A (en) 1964-04-02 1967-01-03 Sandoz Ag Tetracyclic diazepinone compounds
GB1120463A (en) 1964-07-06 1968-07-17 Manuf Prod Pharma Derivatives of 1,3-diazafluoranthene-1-oxide
US3417101A (en) 1964-11-09 1968-12-17 American Home Prod Fused ring compounds
US3329676A (en) 1964-11-09 1967-07-04 American Home Prod Fused 1, 4-diazepine ring systems
US3714149A (en) 1969-11-03 1973-01-30 Upjohn Co Pyridobenzodiazepinones
US3914250A (en) 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
SU930902A1 (ru) 1980-12-18 1982-10-15 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные тиено [3,2=в] индола
US4880814A (en) 1987-11-13 1989-11-14 Abbott Laboratories 7-cycloalkyl naphthyridines
GB8812636D0 (en) 1988-05-27 1988-06-29 Glaxo Group Ltd Chemical compounds
JPH0240379A (ja) 1988-07-28 1990-02-09 Wakunaga Pharmaceut Co Ltd 新規キノロン誘導体
US4997831A (en) 1988-09-01 1991-03-05 Glaxo Group Limited Lactam derivatives
JP2955358B2 (ja) 1989-06-09 1999-10-04 ファルマシア・アンド・アップジョン・カンパニー 中枢神経系活性を有する複素環系アミン
SE9500998D0 (sv) 1995-03-19 1995-03-19 Haakan Wilhelm Wikstroem New sulfone ester analogues of iso-clozapine and related structures: atypical neuroleptics
CA2195697A1 (en) 1996-02-02 1997-08-03 Masahumi Kitano Novel substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof
JPH10237073A (ja) 1996-02-02 1998-09-08 Sumitomo Pharmaceut Co Ltd 新規な置換グアニジン誘導体およびその製法
EP0882047A1 (en) 1996-02-21 1998-12-09 Darwin Discovery Limited Quinolones and their therapeutic use
AU710825B2 (en) 1996-02-21 1999-09-30 Darwin Discovery Limited Quinolones and their therapeutic use
JP2002518451A (ja) 1998-06-22 2002-06-25 エラン ファーマシューティカルズ，インコーポレイテッド 環状アミノ酸化合物およびその医薬組成物、並びにそれら化合物を用いたβ−アミロイドペプチドの放出および／またはその合成を阻害する方法
CA2324474A1 (en) 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
KR20010108025A (ko) 1998-12-17 2001-12-07 이곤 이 버그 5ＨＴ2Ｃ 효능제인2,3,4,4ａ-테트라하이드로-1Ｈ-피라지노(1,2-ａ)퀴녹살린-5(6Ｈ)온 유도체
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
AR023574A1 (es) 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
JP4762465B2 (ja) 1999-06-15 2011-08-31 ブリストル−マイヤーズ スクイブ ファーマ カンパニー 置換複素環縮合ガンマーカルボリン
GB9918965D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
GB9918962D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxii
JP2001089461A (ja) 1999-09-24 2001-04-03 Konica Corp テトラヒドロナフトジアゼピン類の製造方法及びスクアリリウム染料の製造方法
CA2397349A1 (en) 2000-02-29 2001-09-07 Ivan David Horak Farnesyl protein transferase inhibitor combinations with an her2 antibody
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
AR031202A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
US6858604B2 (en) 2000-11-03 2005-02-22 Wyeth Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031201A1 (es) 2000-11-03 2003-09-10 Wyeth Corp /1,4/diazepino/6,7,1-jk/carbazoles y derivados
WO2002036596A2 (en) * 2000-11-03 2002-05-10 Wyeth CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES
US6759405B2 (en) 2000-11-03 2004-07-06 Wyeth Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031198A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de ciclopenta(b)diazepino(6,7,1)indol
US6784172B2 (en) 2000-11-03 2004-08-31 Wyeth Processes for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031195A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta (b) (1,4) diazepino (6,7,1) diazepino (6,7,1-hi) indol
AR031197A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta(b) diazepino(6,7,1-hi)indol
WO2002042304A2 (en) 2000-11-03 2002-05-30 Wyeth Cyclopenta[b][1,4] diazepino[6,7,1-hi]indoles as 5ht2c antagonists
EE200300303A (et) 2000-12-20 2003-12-15 Bristol-Myers Squibb Company Asendatud pürrolokinoliinid ja püridokinoliinid kui serotoniini agonistid ja antagonistid
HUP0303432A3 (en) 2000-12-20 2012-09-28 Bristol Myers Squibb Co Substituted pyridoindoles as serotonin agonists and antagonists and pharmaceutical compositions containing the compounds and their use
WO2003014125A1 (en) 2001-08-06 2003-02-20 Pharmacia & Upjohn Company Therapeutically useful tetracyclic ligands
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents

Also Published As

Publication number Publication date
ES2260631T3 (es) 2006-11-01
EP1497296A1 (en) 2005-01-19
TW200307540A (en) 2003-12-16
US20040034005A1 (en) 2004-02-19
BR0309499A (pt) 2005-02-15
CN101003538A (zh) 2007-07-25
EP1497296B1 (en) 2006-03-22
AU2003263119A1 (en) 2003-11-10
CN1662539A (zh) 2005-08-31
ATE321050T1 (de) 2006-04-15
DE60304188T2 (de) 2006-12-28
JP2005531538A (ja) 2005-10-20
DE60304188D1 (de) 2006-05-11
AU2003263119B2 (en) 2009-05-07
US7012089B2 (en) 2006-03-14
AR039668A1 (es) 2005-03-02
MXPA04010373A (es) 2005-02-03
CA2481324A1 (en) 2003-11-06
CN100376581C (zh) 2008-03-26
JP4537076B2 (ja) 2010-09-01
WO2003091257A1 (en) 2003-11-06
DE60304188T8 (de) 2007-04-19

Similar Documents

Publication Publication Date Title
DK1497296T3 (da) [1,4]Diazocino[7,8,1-hi]indolderivater som antipsykotiske midler og midler mod obesitet
DK1204649T3 (da) Arylmethylcarbonylaminothiazolderivater og deres anvendelse som antitumormidler
IL166202A0 (en) Azolidinone-vinyl benzene derivatives
IL173726A0 (en) N,n-dihalogenated amino acids and derivatives
ATE478870T1 (de) Spiroindolinpiperidinderivate
ATE460418T1 (de) Heterocyclocarboxamidderivate
DE60330372D1 (de) Indol-3-schwefelderivate
ATE467631T1 (de) Chinuclidinamidderivate
ATE438644T1 (de) Chinazolinderivate
DK1474408T3 (da) N-Phenyl-2-pyrimidinaminderivater
DK1497293T3 (da) (1,4)Diazepino(6,7,1-ij)quinolinderivater som antipsykotiske og antiobesitetsmidler
DK1497294T3 (da) 1,2,3,4,7,8-Hexahydro-6H[1,4]diazepino[6,7,1-ij]guinolinderivater som antipsykotiske midler og midler med adiposistas
DK1119557T3 (da) Indeno-, naphto- og benzocyclohepta-dihydrothiazolderivater, fremstilling deraf og anvendelse deraf som anorektiske medikamenter
IL166404A0 (en) Indoline derivatives substituted in
DK1218383T3 (da) Biocykliske imidazo-5-yl-aminoderivater
DK1587788T3 (da) 2,7-substituerede indoler og anvendelsen deraf som 5-HT6-modulatorer
ATE335729T1 (de) 3h-chinazoline -4-on derivaten
AU2003258643A1 (en) Hair colouring agent comprising indole or indoline derivatives
NO20034647L (no) Hydroksyclylalkoksy-, alkyloksy- og -alkylaminobenzazol- derivater som 5-hydroksytryptamin-6-ligander
DK1216250T3 (da) Thienoisoxazolyl- og thienylpyrazolyl-phenoxy- substituerede propylderivater som D4-antagonister
ATE423771T1 (de) Tetrahydrochinolinderivate
AU2003290216A1 (en) Porphyrin derivatives
DK1228041T3 (da) Indolderivater og anvendelse deraf som SHT2A-ligander
DK1532141T3 (da) 2-pyrrolidin-2-yl-[1,3,4]-oxadiazol-derivater og anvendelse deraf som antidepressiv
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate